FDA reviews Merck & Co's Keytruda in new 'tumour agnostic' u...

Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.

AZ, GSK and Cambridge Uni will set up COVID-19 testing centr...

Can we target coronavirus RNA with siRNA drugs?

NEW: RNAi-Based Therapeutics Summit

AstraZeneca on expanding its diabetes research franchise

AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.

GSK eyes nasal polyps use for Nucala after trial success

GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into compet

AZ firms up immuno-oncology imaging deal with ImaginAb